Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330573 | 0.84 | KMT2A (0.63) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL7464838 | 0.80 | KMT2A (0.42) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL4977098 | 0.77 | KMT2A (0.51) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL10285558 | 0.76 | KMT2A (0.44) | SMN1; SMN2KMT2APOLBALDH1A1MEN1 | |
| SCHEMBL1667366 | 0.76 | KMT2A (0.50) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL20748357 | 0.75 | ALDH1A1 (0.39) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL1663786 | 0.75 | ALDH1A1 (0.58) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL228003 | 0.75 | CYP1A1 (0.64) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL2270599 | 0.74 | MAPT (0.60) | RAB9ANPC1SMN1; SMN2HTTKMT2A | |
| SCHEMBL15021162 | 0.74 | RXRA (0.47) | ALDH1A1BACE1CYP2A6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | RAB9A 1172/4885NPC1 13/4885SMN1; SMN2 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.